Tufts Anticipates Regenerative Medicine Market to Touch $68B in 2020

With strong pipelines in Europe, Japan and the U.S., regenerative medicine is poised to become a $68 billion market in the next four years, according to a new report.

The study looks specifically at cell, gene and tissue-engineered therapies within regenerative medicine.

Europe, Japan and the U.S. collectively have 915 regenerative medicines under development, the majority of which are cell therapies, according to the report from the Tufts Center for Study of Drug Development.

In those three regions, the regenerative medicine sector is comprised of 640 private and public companies. Among those companies, 18 received approvals for medicines in the United States for indications such as diabetic foot ulcers and bladder cancer.